MANCHESTER, UK, April 4, 2012 – CN Creative, Ltd. (CNC), a healthcare company providing innovative and sustainable solutions to reduce smoking and smoking-related illnesses, today announced that Tim Byrne has been appointed Chief Financial Officer.
Mr. Byrne, who is a Fellow of the Institute of Chartered Accountants, is an accomplished financial executive whose experience ranges from start-up ventures to international publicly listed companies. Most recently, he was a Founding Partner of The Management Alliance, which provides strategic and financial consulting and management services. Previously, Mr. Byrne was CEO and CFO of Airtours plc, a FTSE 250 listed company with diversified global operations and an annual turnover of £5.2 billion.
CN Creative markets a portfolio of products and services for smoking cessation and harm reduction. The company’s Nicadex™ electronic inhaler nicotine replacement therapy (NRT) is to commence clinical trials shortly and the company intends to submit a Marketing Authorisation Application to the UK Medicines and Healthcare products Regulatory Agency (MHRA) later this year. Regulatory submissions in other European territories and the US will follow.
“Tim’s extensive experience in growing global firms is proving invaluable, and we are delighted to have him as part of CNC’s management team,”
said David Newns, co-founder and Company Director of CN Creative.
“His broad expertise is especially helpful as we are advancing our pioneering electronic inhaler nicotine replacement therapy towards MHRA submission, while also expanding our existing businesses in the UK and overseas.”
Dale R. Pfost, PhD, Chairman of CN Creative and a General Partner at Advent Ventures, commented,
“Tim brings us a global financial perspective and a keen appreciation of how to manage the challenges of high growth companies, and he is well-grounded in the nuts and bolts of implementing the financial management systems critical to our success.”
About CN Creative
CN Creative has developed a portfolio of products and services focused on harm reduction and smoking cessation, including user-friendly nicotine delivery systems and patient-focused smoking cessation and support services, such as QuitDirect, the Intellicig® electronic cigarette, ECOpure high purity nicotine preparations and NRT Direct. CNC’s Nicadex™ electronic inhaler nicotine replacement therapy product is in development for use as part of medically supervised smoking cessation programmes. For more information, visit www.cncbio.co.uk.
For more information, please contact:
CN Creative Media
+1 212 584-2276
David Newns, CN Creative
+44 (0) 7834 767 367